PT-2385 is primarily used in research settings to study and target hypoxia-inducible factor-2α (HIF-2α), a protein that plays a critical role in cellular responses to low oxygen levels. It is being investigated for its potential therapeutic applications in cancers where HIF-2α is overexpressed, such as renal cell carcinoma (RCC). By inhibiting HIF-2α, PT-2385 aims to disrupt tumor growth and survival mechanisms driven by hypoxia. Additionally, it is explored for its effects on conditions where oxygen regulation is impaired, offering insights into novel treatment strategies. Its development underscores its importance in advancing targeted cancer therapies.